Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced the completion of its first export of naturally derived psilocybin to the United Kingdom, supporting a planned Phase 2 clinical trial. The shipment includes psilocybin biomass and finished 5 mg psilocybin capsules manufactured at the company’s GMP facility in Princeton, British Columbia.
The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression, according to the company. They were exported under authorization from Health Canada and the UK Home Office, underscoring the regulatory cooperation between the two countries in advancing psychedelic research.
Optimi Health noted that the products were cultivated, extracted and manufactured in-house under its Drug Establishment Licence, reinforcing its position as a vertically integrated GMP supplier serving both regulated patient access programs and clinical research initiatives. The company’s GMP-compliant facilities in British Columbia produce validated MDMA and botanical psilocybin drug products.
This export marks a significant milestone for Optimi as it expands its international footprint. The company currently supplies active pharmaceutical ingredients and finished dosage forms to clinical and therapeutic programs abroad, with products already prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
The implications of this development are broad. By securing approval from both Health Canada and the UK Home Office, Optimi demonstrates that regulatory pathways exist for cross-border distribution of psychedelic compounds for clinical research. This could pave the way for more international trials and eventual therapeutic access, particularly as mental health crises continue to drive demand for novel treatments.
For Optimi, the export strengthens its business model as a supplier of GMP-grade psychedelic drug products. The company’s vertical integration—from cultivation to manufacturing—positions it to meet growing demand from researchers and clinicians. The UK trial, if successful, could further validate psilocybin’s therapeutic potential and open new markets.
However, challenges remain. Psychedelic therapies face regulatory hurdles and stigma, and commercialization depends on further clinical evidence and approval from bodies like the FDA and EMA. Optimi’s ability to navigate these complexities will be crucial as it seeks to scale operations.
For more information, visit optimihealth.ca or optimi.net. The full press release is available at https://ibn.fm/WLDHZ.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Optimi Health Completes First Psilocybin Export to UK for Planned Phase 2 Trial.